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Treatment prospects for autosomal-dominant polycystic kidney this review is to summarize the observations that already
disease. An increased understanding of the molecular genetic have been made and to discuss therapies for PKD that
and cellular pathophysiologic mechanisms responsible for the deserve investigation.development of autosomal-dominant polycystic kidney disease
(ADPKD), made possible by the advances in molecular biology
and genetics of the last three decades, has laid the foundation
GENETIC MECHANISMSfor the development of effective therapies. As the concept that
a polycystic kidney is a neoplasm in disguise is becoming in- Mechanisms by which mutations to one allele result
creasingly accepted, the development of therapies for ADPKD in a characteristic phenotype include gain of function,
may benefit greatly from the expanding body of information on haploinsufficiency, production of a toxic protein, a domi-cancer chemoprevention and chemosuppression. This review
nant negative effect, and somatic mutation of the allelesummarizes the observations that already have been made and
discusses therapies for PKD that deserve investigation. not affected by the germline mutation. The analysis of
X chromosome inactivation patterns in epithelial cells,
isolated from individual cysts from women with ADPKD,
Adult polycystic kidney disease (PKD) was once has suggested that cysts develop from clonal expansions
deemed to be a rare congenital malformation with a fate of single cells. Analysis of the PKD1 genes in these
predetermined at birth. Recognition of its hereditary cells has revealed a loss of heterozygosity or intragenic
nature nearly a century ago (autosomal-dominant PKD mutations involving the nonaffected PKD1 allele in ap-
or ADPKD) added to the burden of affected individuals. proximately 20% of renal and hepatic cysts [reviewed
More recent studies have shown that the ADPKD kidney in 1] and similar changes involving the PKD2 gene in
forms normally and that macroscopic cysts develop PKD2 cystic epithelium [7–9]. These observations sup-
mainly after birth. It is the most common life-threatening port a two-hit model of cystogenesis, which is consistent
monogenetic human disease and the third most common with the inactivating nature of most germline PKD1 and
single cause of end-stage renal failure behind hyperten- PKD2 mutations [10, 11] and the focal development of
sion and diabetes mellitus. Advances in molecular biol- renal and hepatic cysts. The mild cystic phenotype of
ogy and genetics in the last three decades have made Pkd1 or Pkd2 heterozygote and the severe fetal cystic
possible a greater understanding of the molecular genetic changes of homozygote mutant mice indicate that cysto-
and cellular pathophysiologic mechanisms responsible genesis is associated with polycystin loss [2]. The more
for the development of ADPKD, and have laid the foun- severe cystic disease in Pkd2WS25/WS25 and Pkd2WS25/2 mice,
dation for the development of effective therapies [re- associated with the Pkd2 WS25 unstable allele (gener-
viewed in 1–4]. As the concept that a polycystic kidney ated by tandem integration of a mutant exon 1 into the
is a neoplasm in disguise is gaining acceptance [5], the first intron of Pkd2), which results in an increased rate
development of therapies for ADPKD may benefit from of somatic mutations by intragenic homologous recombi-
the expanding body of information on cancer chemo- nation, further supports the two-hit mechanism. The mild
prevention and chemosuppression [6]. The purpose of cystic phenotype of Pkd1 or Pkd2 heterozygote mutant
mice [12, 13] may point to different susceptibilities of
murine Pkd and human PKD genes to somatic mutations.Key words: antimutagens, antioxidants, soy protein, fish oil, EGF re-
ceptor, tyrosine kinase inhibitors. The human PKD1 gene might have a higher susceptibil-
ity due to polypyrimidine tracts, which may facilitateReceived for publication September 29, 2000
triple helixing, erroneous DNA repair, and mutagenesisand in revised form November 22, 2000
Accepted for publication December 1, 2000 during transcription [14], or to the existence of homolo-
gous PKD1 genes (HG), which may predispose to somaticÓ 2001 by the International Society of Nephrology
2005
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mutations by gene conversion events [15]. The high rate [28, 29]. If these transheterozygous mutations are patho-
genetically important, it seems likely that mutations inof somatic mutations in the PKD2 gene remains unex-
plained. Of note is the variable development of the ex- multiple other genes encoding proteins that may be part-
ners of the polycystins in the same signaling pathwaypected renal phenotype in other targeted mutant mouse
models for diseases in which a two-hit mechanism is may also occur.
The understanding of the molecular genetic mecha-likely. For example, heterozygote mutant mice for Von
Hippel-Lindau (VHL) disease remain phenotypically nisms responsible for the cystic disease in ADPKD has
treatment implications. If somatic mutations of eithernormal up to 15 months of age [16], while heterozygote
tuberous sclerosis complex 2 (TSC2) mutant mice consis- one or multiple genes were important, treatments di-
rected at reducing the rate of mutations should be consid-tently develop renal cell carcinomas by 6 months of age
[17]. Therefore, other mechanisms may need to be con- ered. Their effectiveness would depend on whether the
somatic mutations occur mostly during the development,sidered to account for the different phenotypic expres-
sion of PKD mutations in humans and mice. The differ- maturation, and growth of the kidney or at later stages
in association with environmental exposures and cellularent phenotypic expression of these diseases may simply
reflect differences in life span, which determines whether senescence. If the hypothesis that ADPKD is a recessive
disease at the cellular level was confirmed, gene replace-somatic mutations develop in the kidney, an organ that
may be particularly susceptible because of its high oxida- ment therapy would be theoretically possible. The feasi-
bility of gene replacement therapy has been demon-tive metabolism [18], as well as other factors that cur-
rently are not understood. strated by the rescue of the renal phenotype in the Oak
Ridge National Laboratory polycystic kidney (orpk)Whether somatic mutations of the PKD allele not af-
fected by the germline mutation are the only, or even model by the expression of the wild-type orpk gene as
a transgene [30]. The expression of PKD1 as a transgenethe most important, mechanism responsible for cyst for-
mation in ADPKD has not been definitely established. has also been shown to rescue the embryonically lethal
The overexpression of polycystin 1 in the cystic epithe- phenotype associated with the Pkd1del34/del34 knock-out
lium detected immunohistochemically by C-terminal an- mouse [27]. Technical considerations, such as the re-
tibodies [reviewed in 4] can only be explained, within quirement for a highly selective, efficient, and durable
the context of the two-hit model, if the majority of second gene transfer to somatic cells, safety issues, and the ob-
hits involve in-frame missense mutations rather than servation that the overexpression of PKD1 also results
truncations or deletions. This may be particularly impor- in a cystic phenotype cast doubt on the feasibility of
tant in the TSC2/PKD1 contiguous gene syndrome and gene therapy as a successful treatment for ADPKD.
in early ADPKD, in which overexpression of polycystin
1 is more uniformly observed [19]. The extensive renal
THE FUNCTION OF POLYCYSTINScystic disease observed in the PKD1/TSC2 contiguous
The predicted structures of the polycystins suggestgene syndrome and early onset ADPKD would require
that they are membrane-associated proteins capable ofan extremely high rate of somatic mutations or somatic
physical interaction, but their function remains uncertainmutations occurring in stem cells at an early stage of
[reviewed in 1–4]. Recent evidence supports the conceptnephrogenesis. If the latter was correct, many cysts in
that they participate in the regulation of cell–matrix andthese conditions would share the same somatic muta-
cell–cell interactions and, by so doing, of cell differentia-tions, a hypothesis that has not yet been tested. The
tion, proliferation, and apoptosis. Polycystin 1 has beenincreased rate of proliferation and apoptosis observed
found to be a component of large multiprotein complexesin many noncystic tubules cannot be explained by the
associated with cell–matrix contacts at focal adhesionstwo-hit hypothesis unless the rate of second hits is much
and intercellular contacts at adherens junctions and des-higher than that suggested by the number of cysts [20–22].
mosomes [31, 32]. Polycystin 2 is expressed in the endo-Focal development of cysts has also been observed in
plasmic reticulum membrane of cells in tissue culture,autosomal recessive models [22, 23], as well as in trans-
and its C-terminus contains a 34 amino acid region essen-genic models of PKD [24–26]. Overexpression of PKD1
tial to this localization [33]. Possibly the physical interac-as a transgene results in the development of a cystic
tion between polycystin 1 and polycystin 2 is importantphenotype, suggesting that the maintenance of a normal
for the trafficking of these proteins to the plasma mem-level of polycystin may be critical to maintain a differen-
brane.tiated tubular epithelial phenotype [27]. Transheterozy-
Cell–matrix interactions in focal adhesions are medi-gous mutations of PKD1 and PKD2 (for example, so-
ated by integrin receptors (Fig. 1). These are heterodi-matic mutations of PKD2 in cells carrying a germline
meric molecules composed of a and b subunits, of whichPKD1 mutation) have been recently reported and pro-
there are multiple subtypes with specificity of binding toposed to explain the continued expression of polycystin
1 and polycystin 2 in ADPKD1 and ADPKD2 kidneys different matrix components [34]. Binding to specific
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Fig. 1. Schematic representation of the interaction between focal adhesions, adherens complexes, Wnt signaling, and mislocalization of growth
factor receptors. Hypothetical up-regulation and down-regulation of these systems in polycystic kidney disease (PKD) are depicted by arrows
within circles.
ligands induces clustering of integrin heterodimers and the adherens junction and desmosomes and by ubiquitin-
proteasome–mediated degradation following phosphoryla-assembly of a multiprotein complex, which includes struc-
tural actin binding proteins such as tensin, vinculin, talin, tion by glycogen synthase kinase-3b (Gsk3b) in a multipro-
tein complex that also includes the adenomatous polyposisand a-actinin, as well as the tyrosine kinases focal adhe-
sion kinase (FAK) and c-src. This provides a mechanism coli (APC) protein, axin, and protein phosphatase-2A.
The degradation of b-catenin can be inhibited by secretedfor signal transduction leading to alterations in gene tran-
scription. Cell–cell interactions at adherens junctions and Wnt glycoprotein acting upon its receptor Frizzled, which
activates Disheveled (Dvl) and inhibits Gsk3b. Free cyto-desmosomes are mediated by classic and desmosomal
cadherins (Fig. 1). These are single-pass transmembrane solic b-catenin can translocate to the nucleus, where it
binds and activates the lymphoid-enhancing transcriptionadhesion proteins, capable of forming lateral dimers in
a calcium-dependent manner [35]. The cytoplasmic do- factor (LEF-1) T-cell factor (TCF). One of the target
genes of the b-catenin/LEF-1 transcription factor is c-myc,mains of these proteins connect directly to b-catenin or
g-catenin, which function as a bridge with a-catenin and which is overexpressed in PKD.
The precise localization and the role of polycystins incytoskeleton molecules such as a-actinin, vinculin, and
F-actin. There is evidence for cross-talk between focal cell–matrix and cell–cell contacts are not firmly estab-
lished. Wilson et al have detected a direct physical associ-and adherens junctions. In many cellular systems, cadh-
erin activity is under the dual control of signaling path- ation between polycystin 1 and a2 and b1 integrins, vin-
culin, paxillin, and FAK during the initial adherence ofways activated by focal adhesions and growth factor re-
ceptors. Tyrosine phosphorylation of the NH2-terminus fetal collecting tubule epithelial cells to type 1 collagen
matrix [31]. On the other hand, Huan and van Adelsbergof b-catenin results in dissociation of the entire cadherin
catenin complex from the cytoskeleton. have observed the colocalization of polycystin 1 with
E-cadherin and a, b, and g-catenins, but not with FAKb-Catenin is a bifunctional protein that is not only
involved in cell–cell adhesion by its link to E-cadherin, or b1-integrin, in human fetal kidney [32]. Scheffers et al
have reported the colocalization of polycystin 1 with des-but also functions as a transcription factor (Fig. 1) [36, 37].
Cytosolic b-catenin levels are regulated by binding to mosomes (abstract; Scheffers M, Netherlands PKD Work-
Qian et al: Treatment prospects for ADPKD2008
shop, 2000). These different results may reflect the state because of an impaired basolateral trafficking of proteins
and a delayed exit from the Golgi apparatus [42]. Theof maturity of the epithelial cells. Thus, in subconfluent
cells, polycystin 1 may associate with classic proteins of reduced levels of E-cadherin in the cystic epithelium may
explain the increased rate of apoptosis in ADPKD kidneysfocal adhesions, while it forms multiprotein complexes
typical of adherens junctions and desomosomes in con- since cell–cell adhesion inhibits apoptosis in the renal
tubules by an E-cadherin–dependent mechanism [43]. Influent epithelia.
The mechanisms by which a loss or reduced level of addition, the reduced sequestration of b-catenin by the
E-cadherin complexes may result in higher cytoplasmicpolycystin 1 might disrupt normal cell–matrix or cell–cell
interactions are just beginning to be ascertained. Several levels. Consistent with this is the observation by Huan
and van Adelsberg of a prolonged half-life of b-catenin ininvestigators have described abnormal cell–matrix inter-
actions in ADPKD-derived epithelial cells. Wilson et al immortalized cell lines isolated from cpk mice (abstract;
Huan Y, 33rd ASN Meeting, 2000). An important role forfound that ADPKD-derived cells express higher levels
of a2 and b1 integrins and matrix attachment compared b-catenin in the pathogenesis of ADPKD is also supported
by the observations that transgenic mice expressing largewith normal epithelial cells. In addition, they were able
to coimmunoprecipitate polycystin 1 and FAK from nor- amounts of a NH2-terminally truncated b-catenin de-
velop severe PKD [44], that the expression of c-myc (amal, but not from ADPKD, epithelial cell extracts and
suggested that an alteration in polycystin 1 phosphoryla- target of b-catenin/LEF-1) is up-regulated in the cystic
epithelium from human ADPKD and rodent models oftion, resulting from an impaired association with FAK,
could be responsible for a failure to down-regulate integ- PKD, that overexpression of c-myc as a transgene in-
duces the development of PKD [26], and that treatmentrin-mediated epithelial cell adhesion [31]. Huan and van
Adelsberg also observed an increased b1 integrin-medi- with c-myc antisense oligonucleotides reduced the sever-
ity of the cystic disease in cpk/cpk mice (abstract; Rickerated adhesion to extracellular matrix in cells from poly-
cystic kidneys in the cpk mouse. These investigators, J, 32nd ASN Meeting, 1999). If the role of b-catenin in
however, suggested that the up-regulation of b1 integrin- the pathogenesis of PKD is confirmed, treatment strate-
mediated adhesion was secondary to a disruption of the gies to down-regulate its expression or activity could be
normal interaction between polycystin 1 and the E-cad- considered.
herin/catenin complexes, and that it might represent an
example of cross-talk between cadherins and integrins
DOWNSTREAM PATHOGENETIC EVENTS[32]. Daikha-Dahmane et al found a marked increase in
While the exact molecular genetic and biochemicala1 integrin staining in normal and cystic collecting duct
mechanisms that initiate the development of the cysticcells and a severe disorganization of the expression and
disease in ADPKD have not been firmly established,distribution of other integrins in the cyst lining cells from
they result in a clonal expansion of partially differenti-ADPKD and ARPKD kidneys [38]. The role of cell–
ated epithelial cells characterized by disregulation of epi-matrix interactions in the pathogenesis of PKD is sup-
thelial cell proliferation and apoptosis, expression of aported by the renal cystic phenotype of tensin knockout
secretory phenotype, and a disarray of cell matrix inter-mice [39].
actions that leads to interstitial inflammation and matrixA number of recent studies suggest that polycystin 1
accumulation (Fig. 2). In addition, the cysts produce aparticipates in the regulation of cell–cell interactions in
number of factors capable of affecting in an autocrinerenal tubular epithelial cells and that a disruption of these
and paracrine fashion the development and enlargementinteractions may be an early event in the pathogenesis
of neighboring cysts. These include growth factors, che-of ADPKD. Rocco et al first reported an attenuated ex-
mokines, proinflammatory cytokines, nucleotides, bioac-pression of the epithelial cell adhesion molecules N-CAM
tive lipids, matrix metalloproteinases, lysosomal enzymes,and E-cadherin at mRNA and protein levels in the kid-
and vasoactive factors [reviewed in 45, 46]. Recent micro-neys of cpk/cpk mice, and suggested that a defect in cell
puncture and microdissection studies have demonstratedadhesion receptors in the cystic renal epithelium may
that tubular obstruction is a feature of PKD in some animalplay an important role in the pathogenesis of cyst forma-
models and may contribute to the growth, if not thetion and altered function of cystic epithelium [40]. More
development, of the cysts [47]. Several investigators haverecently, Kim et al observed that the expression of the
drawn attention to the similarities between the patho-C-terminal domain of polycystin as a membrane-bound
genesis of renal cystic disease and obstructive nephropa-fusion protein stabilizes soluble endogenous b-catenin
thy. Nephroangiosclerosis develops early in ADPKDand stimulates LEF-1–dependent gene transcription in
and probably contributes significantly to the progressionhuman embryonic kidney cells [41]. Charron et al have
of the renal disease and decline in renal function. Pari-reported that the epithelial cells from polycystic kidneys
passu with this downstream pathogenetic event, the anal-not only have reduced levels of E-cadherin, but that this
protein is improperly sequestered in an intracellular pool ysis of the signal transduction pathways in cells derived
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Fig. 2. Schematic representation of pathogenetic events and treatment strategies in PKD. Pathogenetic events are shown in shaded boxes, and
treatment strategies are shown in open boxes.
from cystic epithelium has demonstrated multiple abnor- late the development of PKD and be a target for therapy
would be warranted.malities (Fig. 3). The increasing understanding of the
Oxidant species are generated during metabolic pro-abnormalities in cell–matrix and cell–cell communication,
cesses and contribute to the regulation of cell prolifera-endocrine, paracrine and autocrine mechanisms, and sig-
tion and differentiation under normal conditions and tonal transduction pathways in ADPKD has provided a
tissue injury in response to pathologic stresses. Damageframework for the delineation of possible therapies and
to DNA by oxidant species appears to occur naturally,opportunities for synergistic interventions in ADPKD.
and low steady-state levels of base-damaged products
can be detected in nuclear DNA from human cells and
ANTIMUTAGENS AND ANTIOXIDANTS tissues. It has been calculated that the total number of
If somatic mutations are important for the develop- oxidative hits to the DNA per cell per day in humans
ment of the cystic lesions of ADPKD, which is an increas- may be more than 104 [49]. A number of observations
ingly accepted hypothesis, then treatments capable of suggest that the severity of PKD can be modulated by
reducing the rate of somatic mutations may be able to oxidative stress, and depletion of glutathione by the ad-
slow down the progression of the disease. This could in- ministration of buthionine sulfoximine aggravates the
clude drugs capable of preventing the activation of en- development of PKD in Han:SPRD rats [reviewed in
dogenous and exogenous mutagens (inhibitors of phase 50]. The evidence for a protective effect of antioxidants
1 enzymes) or of enhancing their detoxication (inducers on the development of PKD is more limited. The admin-
of phase 2 enzymes). This approach has not yet been istration of probucol to pcy mice fed a high-protein diet
tried for ADPKD. One study has demonstrated an up- had a protective effect, possibly as a consequence of its
regulation of the cytochrome P450 1B1 in the Han:SPRD antioxidant action [51]. On the other hand, the dietary
rat [48]. If a similar up-regulation of this enzyme could content of a-tocopherol, a major lipophilic antioxidant
be demonstrated in other models of renal cystic disease, of cell membranes, did not have a significant effect on
the severity of the PKD in Han:SPRD rats [52]. Possiblyfurther studies to determine whether CYP1B1 can modu-
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Fig. 3. Schematic representation of the interaction of hormones, growth factors and cytokines, retinoids, and cell–cell and cell–matrix interactions
and of their signaling pathways in renal tubular epithelial cells. Signaling molecules known to be altered in PKD are shown in shaded boxes.
Multiple steps of these signaling pathways can be targeted for intervention.
other cytosolic antioxidants and antioxidant enzymes are ciated with a high-protein diet may result in an enhanced
synthesis rate of adenosine 59-triphosphate (ATP), butmore important in the pathogenesis of PKD.
the steady-state tissue concentrations of ATP have not
been found to be different [55]. Enhanced ammoniagen-
DIETARY AND METABOLIC INTERVENTIONS esis, oxidative stress, and extracellular release and para-
Studies in animal models of PKD have clearly demon- crine effect of ATP have all been proposed as potential
strated that its development can be markedly influenced mechanisms of renal cystic disease progression in
by dietary interventions. While protein restriction consis- ADPKD. In addition, alterations in dietary protein have
tently ameliorates it, the administration of a high-protein been shown to alter the activity of the renal renin-angio-
diet dependably aggravates renal cystogenesis in pcy tensin system and the expression of transforming growth
mice and Han:SPRD rats [53, 54]. The responsible mech- factor-b (TGF-b), which can also affect renal cystic dis-
anisms are not clearly established. In the remnant kidney ease progression [53, 54].
model, a high-protein diet has been associated with a Not only the protein content, but the protein composi-
lower arterial pH, higher intracellular pH and inorganic tion of the diet may influence the development of PKD.
phosphate, higher oxygen consumption, higher genera- Soy protein-based diets have a beneficial effect on the
tion of oxygen-free radicals, higher oxidized:reduced glu- development of PKD in the Han:SPRD rat and in the
tathione ratios, and increased ammoniagenesis, while the pcy mouse, as compared with casein-based diets [56–58].
reverse occurs during protein restriction. The increased The mechanism underlying this beneficial effect has not
been established. Soy protein contains several phytoes-intracellular concentration of inorganic phosphate asso-
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trogens or soy isoflavones, including genistein, which is tions in the studies using a soy protein and flaxseed diet.
Possibly, autoxidation of the v3-PUFA or an oxidatingan inhibitor of tyrosine protein kinases. The addition of
genistein in an amount comparable to that present in a or nephrotoxic effect of the antioxidant ethoxyquin
added to the fish oil preparation might have been respon-soy protein-based diet, however, did not have a beneficial
effect [56]. Since soy protein has a high l-arginine/l-lysine sible for the detrimental effect.
The possibility that renal ammoniagenesis or linkedratio compared with casein, the possibility exists that the
beneficial effect of soy protein is related to an increased metabolic processes could have an effect on the progres-
sion of PKD was suggested by an association betweenproduction of nitric oxide [56]. However, the administra-
tion of l-arginine has been found to have only a very chronic hypokalemia and acquired renal cysts [reviewed
in 64]. Acquired renal cysts are also observed in chronicmodest beneficial effect on the development of renal cystic
disease in the Han:SPRD rat [59]. An intriguing study renal failure, both clinically and experimentally, and in
patients with distal renal tubular acidosis. Increased renalrelates the beneficial effect of a soy protein diet to its
effect on polyunsaturated fatty acid metabolism [58]. In ammoniagenesis, either in absolute terms or relative to
the number of surviving nephrons, is common to thesethis study, soy feeding was associated with higher renal
and hepatic linoleic acid content, higher hepatic a-linole- conditions. The link of an enhanced cortical production of
ammonia associated with renal mass reduction, chronicnic acid, and lower hepatic arachidonic acid content,
changes consistent with the reported effect of soy protein hypokalemia, and dietary deficiency of antioxidants to
the development of interstitial inflammation and fibrosisfeeding to decrease the hepatic activity of D6-desaturase,
the first step in the conversion of the essential v6-polyun- in these conditions suggested that a similar mechanism
could be operative in PKD, as a result of a defectivesaturated fatty acid (v6-PUFA) to the eicosanoid precur-
sor arachidonic acid (Fig. 4) [60]. It has been suggested transfer of ammonia to the final urine analogous to that
observed after subtotal nephrectomy [reviewed in 64].that the beneficial effect of the soy protein may be due
to the reduced production of arachidonic acid. Finally, Therefore, the demonstration that the administration of
the administration of soy protein results in lower levels sodium bicarbonate or potassium bicarbonate or sodium/
of insulin-like growth factor-1 (IGF-1) in the kidneys of potassium citrate markedly attenuates the development
Han:SPRD cy/1 rats, suggesting a role for the IGF system of PKD in the Han:SPRD rat seemed to provide a strong
in its beneficial effect [61]. rationale for the study of this safe and economical form
The administration of flaxseed supplementation, a rich of treatment in human ADPKD [64, 65]. Unfortunately,
source of a-linolenic acid, has also been reported to ame- this beneficial effect has not been confirmed in other ani-
liorate the interstitial nephritis associated with the renal mal models of PKD. In fact, the administration of sodium
cystic disease in Han:SPRD rats [62]. The mechanism re- bicarbonate or sodium/potassium citrate to pcy mice has
sponsible for this beneficial effect is thought to be through no beneficial effect and can be detrimental [66, 67]. More
competition with linoleic acid for D6-desaturase and a recently, the administration of sodium bicarbonate to
reduction in arachidonic acid synthesis (Fig. 4) [58]. In pck rats has been found to markedly aggravate the devel-
addition, a-linolenic acid is converted into eicosapenta- opment of the PKD (abstract; Qian Q, 33rd ASN Meeting,
noic acid (EPA), which displaces arachidonic acid from 2000). These opposing effects of base administration may
the cell membranes. EPA competes effectively for avail- be related to the origin of the cysts from different neph-
able cycloxygenase and lipooxygenase activity, and the ron segments in these animal models. In the Han:SPRD
prostanoids and leukotrienes derived from EPA (3-series rats, the cysts develop from the proximal tubules. In the
PGs and 5-series LTs) are less inflammatory and chemo- pcy mouse, the cysts originate from the distal tubules
tactic than those derived from arachidonic acid [AA; and collecting ducts. In the pck rats, the cysts derive
2-series prostaglandins (PGs) and 4-series leukotrienes from the thick ascending limb of Henle, distal tubules,
(LTs)]. The beneficial effect of flaxseed may also be due to and collecting ducts. The investigation of the mecha-
its high content of lignans, a main class of phytoestrogens. nisms responsible for these different responses is likely
In contrast to the observations with soy protein diet to provide an insight into the role of metabolic factors
and flax oil supplementation, the administration of fish in the modulation of renal cystogenesis.
oil, a rich source of v3-PUFA EPA and docosahexaenoic
(DHA) acids, has a long-term detrimental effect on renal
ErbB RECEPTORS AND TYROSINEfunction and survival in pcy mice [63], despite a possible
KINASE INHIBITORSearly beneficial effect in the short term. The administra-
A number of elegant studies during the last decadetion of a fish oil diet reduced the renal content of tissue
have provided evidence for a major role for the epider-arachidonic acid, which was replaced by EPA and DHA.
mal growth factor (EGF)-TGF-a-EGF receptor (EGFR)The authors suggested that the detrimental effect might
axis in promoting epithelial hyperplasia and cyst forma-have been due to a reduction in renal prostaglandin E2
production, but this seems inconsistent with the observa- tion and enlargement, and for its potential as a target
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Fig. 4. Schematic representation of the metabolism of omega-3 and omega-6 fatty acids. The carbon at the methyl group is referred to as the v-carbon.
v-3 Fatty acids (FAs) have a double bond between the third and fourth carbon from the v-carbon (v-3 or n-3). v-6 FAs have a double bond
between the sixth and the seventh carbon from the v-carbon (v-6 or n-6). The v-3 a-linolenic (LNA) and the v-6 linoleic (LA) acids are essential
FAs. Their metabolism involves increases in chain length and degree of unsaturation by the addition of extra double bonds. There is competition
between the v-3 and v-6 FAs for the desaturases. LNA is converted to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). LA is
converted to arachidonic acid (AA). The metabolites derived from EPA are less inflammatory and chemotactic than those derived from AA. Soy
protein feeding decreases the hepatic activity of D-6 desaturase. Fish oil is a rich source of EPA and DHA. Rose and Connolly discuss more about
the v-3 fatty acids [60].
for treatment in PKD. EGF and TGF-a are the best cascades and the activation of particular transcription
factors that lead to either cell proliferation or differentia-known of a large family of EGF-related peptide ligands
for a family of four structurally-related tyrosine kinase tion depending on cell–matrix and cell–cell interactions
[69]. Internalization of the ligand receptor complex fol-receptors known as ErbB receptors [68]. The EGFR,
also known as ErbB-1, is the receptor for EGF and TGF-a. lows the binding of the ligand and activation of the recep-
tor. Internalized receptors into clathrin-coated vesiclesErbB-2, which is expressed at low levels in normal epi-
thelial cells, has no recognized high-affinity ligand. ErbB-3 are still capable of eliciting mitogenic signals. The fate
of the internalized receptors depends on the nature ofand ErbB-4 and their ligands are shown in Figure 5.
The binding of an EGF-like peptide to the extracellular the ligand. When the ligand is TGF-a, internalized recep-
tors are recycled to the cell membrane, whereas EGF-domain of an ErbB receptor results in receptor dimeriza-
tion, tyrosine kinase activation, and autophosphoryla- bound receptors are targeted for degradation.
Although the expression of EGF mRNA and proteintion. A large number of cytoplasmic proteins, containing
phosphotyrosine binding motifs, such as Grb-2, phospho- is markedly down-regulated in the kidneys of cpk and
pcy mice and of Han:SPRD rats [70, 71], renal cyst fluidslipase Cg (PLCg), Src, and many others, engage the acti-
vated ErbB receptors. The response triggered by specific from ADPKD, autosomal-recessive polycystic kidney
disease (ARPKD), and murine and rat PKD models con-growth factors includes diverse intracellular signaling
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Fig. 5. Schematic representation of an ErbB receptor, different types, and their ligands. The numbers in the boxes represent the percentage
homology to the corresponding domains of ErbB-1. Reproduced by permission from Klapper et al [67].
tain multiple EGF or EGF-like peptides in mitogenic ment of postnatal kidney explants from bpk mice with
the EGFR tyrosine kinase inhibitor EKI-785 markedlyconcentrations [72, 73]. The expression of TGF-a mRNA
and protein is increased in ADPKD kidneys [73]. EGFR reduced the number of collecting tubule cysts [81]. The
in vivo role for increased EGFR activity was demon-is overexpressed and mislocated to the apical surface of
cystic epithelial cells in human ADPKD and ARPKD, as strated by breeding mice carrying the waved-2 mutation,
a point mutation that decreases EGFR tyrosine kinasewell as in the cpk, bpk, and orpk mouse models of PKD
[74, 75]. Apically expressed EGFRs exhibit high-affinity activity, and orpk mice [82]. Animals homozygous for
both mutant genes (orpk and waved-2) had a markedbinding for EGF, autophosphorylate in response to EGF,
and transmit a mitogenic signal when stimulated by the reduction in the formation of collecting tubule cysts and
an improvement in renal function. Finally, the adminis-appropriate ligand. Overexpression of ErbB-2 has also
been detected in a small number of patients with ADPKD tration of the novel tyrosine kinase inhibitor EKI-785
to bpk mice markedly reduced collecting tubular cysticbut not in those with ARPKD [76]. Transgenic mice that
overexpress TGF-a develop renal cystic disease and re- lesions, improved renal function, and increased the life
span of these animals [75].nal expression of TGF-a as a transgene accelerates the
progression of the PKD in pcy mice [24, 77]. The expres- The interest on the inhibition of EGFR extends be-
yond the treatment of ADPKD and is an area of intensesion of ErbB-2 as a mouse transgene causes multifocal
hyperplasia of renal tubular epithelial cells and cyst for- investigation for the prevention and treatment of neo-
plastic diseases in many academic centers and pharma-mation [25]. EGF and TGF-a are cystogenic in a variety
of in vitro systems [78, 79]. Treatment of murine meta- ceutical companies [83, 84]. A link between activation
of EGFR and ErbB-2 receptors and human cancer hasnephric organ cultures with the tyrosine kinase inhibitors
tyrphostin or genistein inhibits the development of EGF been convincingly demonstrated. Several reversible and
irreversible EGFR tyrosine kinase inhibitors, with excel-and TGF-a–induced proximal tubule cyst formation in
explants from normal mice and induces proximal tubule lent potency and selectivity and limited toxicity, are cur-
rently in phase 1 or phase 2 clinical trials.cyst regression in explants from bpk mice [78, 80]. Treat-
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Fig. 6. Post-translational modifications of Ras required for its attachment to the plasma membrane, which is a prerequisite for its activation.
Ras INHIBITORS in Han:SPRD cy/1 rats, possibly by inhibiting farnesyl
synthesis and Ras farnesylation [89].The Ras genes code for a family of guanosine triphos-
phate (GTP) binding proteins, with endogenous guano-
sine triphosphatase (GTPase) activity, which cycle be- cAMP ANTAGONISTS AND PROTEIN KINASE
tween an active GTP-bound and an inactive guanosine A TYPE 1 INHIBITORS
diphosphate (GDP)-bound state and have a central role
The activation of adenyl cyclase and generation ofin the cellular signal transduction cascade [85]. The par-
cAMP promote the secretion of solutes and fluid intoticipation of Ras proteins in the pathogenesis of PKD is
the cysts [90, 91]. Recent studies have suggested thatsupported by the increased renal expression of H-ras
cAMP may also promote cell proliferation in polycysticand K-ras in cpk mice and human ADPKD, as well as
kidneys and a variety of neoplastic tissues, includingby the renal cystic phenotype of Ras transgenic mice
renal cell carcinoma [92–94]. Yamaguchi et al found that[86]. The activation of Ras requires attachment to the
receptor-mediated agonists of adenyl cyclase, forskolin,plasma membrane, which is dependent on a number of
and 8-Br-cAMP activate the extracellular signal regu-post-translational modifications (Fig. 6). The most cru-
lated kinase (ERK) cascade and increase cellular prolif-cial of these modifications is the attachment of a farnesyl
eration in cells derived from polycystic kidneys, but thatgroup to a C-terminal cysteine by the enzyme farnesyl-
they had an inhibitory effect on cells derived from nor-transferase, which recognizes a carboxyl terminal CAAX
mal human kidney cortex [92]. The proliferative effectmotif. This enzyme can be inhibited by molecules that
on ADPKD derived cells was complementary and addi-resemble either the 15 carbon farnesyl donor or the Ras
tive to that caused by EGF. While the effect of EGFCAAX motif. Several of these drugs are currently in
was blocked by genistein, a receptor tyrosine kinase in-phase 1 and phase 2 clinical trials for neoplastic diseases
hibitor, the cAMP-dependent proliferation was not. Theand appear to have minimal toxicity [87, 88]. The possi-
effect of cAMP, but not that of EGF, was blocked by ability that these drugs may be effective to treat PKD is
cAMP-dependent protein kinase [protein kinase A (PKA)]suggested by the observation that the administration of
inhibitor. Both effects, those of EGF and of cAMP, werelovastatin, an HMG-CoA reductase inhibitor, had a ben-
eficial effect on the development of renal cystic disease blocked by a mitogen extracellular kinase (MEK recep-
Qian et al: Treatment prospects for ADPKD 2015
tor) inhibitor. From these observations, these authors INHIBITORS OF PROTEIN KINASE EFFECTORS
concluded that cAMP stimulates the proliferation of The activation of Ras triggers a protein kinase cascade,
ADPKD, but not normal kidney, epithelial cells by PKA which includes Raf and MEK. Kinase inhibitors of Raf
activation of the ERK pathway at a place distal to the and MEK are in early stages of development, while Raf
receptor tyrosine kinase and proximal to MEK (Fig. 3). antisense oligonucleotides are in phase 2 clinical trial for
The role of cAMP and PKA on the regulation of cell a number of carcinomas, including renal cell carcinoma
proliferation in a variety of neoplastic tissues, including [97]. One of the MEK inhibitors, PD-098059, has been
renal cell carcinoma, has received recent attention and shown to block the proliferative effect of EGF and cAMP
may be relevant to ADPKD [94–96]. The effects of on ADPKD-derived epithelial cells in vitro [92].
cAMP on mammalian cells are mediated by binding to
either of two distinct isoforms of PKA, known as PKA1
INHIBITORS OF LIPID-MEDIATED SIGNALINGand PKA2. PKA1 and PKA2 share identical catalytic
The activation of hormone, growth factor, and cyto-(C) subunits, but differ in the regulatory (R) subunits
kine receptors is also associated with changes in phos-termed R1 in PKA1 and R2 in PKA 2. The PKA holoen-
pholipid and sphingolipid metabolism, and results in thezyme is a tetramere formed of two identical regulatory
generation of bioactive lipid signaling molecules. A num-and catalytic subunits. Upon cAMP binding to the R
ber of abnormalities in the levels of these bioactive lipidsubunits, the active C subunits are released. The relative
molecules have been described in PKD in humans andabundance of PKA1 and PKA2 isoforms is regulated
in rodents.during differentiation, cell growth, and neoplastic trans-
The phosphorylated residues on the intracellular do-formation. Increased levels of PKA1 are detected in neo-
main on the growth factor receptors bind and activateplastic and proliferating cells, whereas a predominant
PLC-g, which cleaves phosphatidylinositol (4,5)-bisphos-expression of PKA2 is found in growth-arrested cells.
phate (PIP2) into diacylglycerol (DAG; Fig. 3). The levelsThere is evidence for functional cross-talk between li-
of PIP2 in the kidneys of pcy mice have been found togand-induced EGFR activation and PKA1 expression and
be markedly reduced, probably reflecting an increasedfunction. PKA1 is overexpressed and activated following
PLC-g activity [98]. DAG activates some forms of proteinTGF-a–induced transformation in several rodent and
kinase C (PKC) such as PKC-a, which are involved inhuman cell lines. Ciardiello and Tortora have proposed
cell proliferative processes [99]. PKC-a antisense oligo-that EGFR and PKA1 interact by direct binding of the
nucleotides and inhibitors of PKC kinase activity, whichR1 subunit to the Grb2 adaptor protein, downstream
are in phase II clinical trials for neoplastic disease, mayof EGFR, but upstream of the ERK pathway, which is
be of value to treat PKD.
consistent with the observations made in ADPKD-derived
The activation of Ras results in the activation of phos-
epithelial cells [94]. PKA1 may also activate MEK through phatidylinositol-3 kinase (PI3K; Fig. 3). The product of
the intermediacy of Rap-1 and B-Raf, as has been re- this reaction, phosphatidylinositol-3 phosphate (PI3P),
cently been described in PC-12 and COS cells, which are is able to activate the protein kinase Akt (also known
stimulated to proliferate by cAMP [reviewed in 92]. as protein kinase B or PKB), which is a suppressor of
The observation that cAMP and PKA activation pro- apoptosis [100]. An increased formation of PI3P after
motes the proliferation of neoplastic and ADPKD-derived intraperitoneal injection of 3H-myoinositol, which proba-
epithelial cells has important therapeutic implications. bly reflects the activation of PI3K, has been described
A new class of cAMP analogues can discriminate be- in pcy mice [98]. In addition, an increased expression of
tween the two cAMP binding sites on R1 and R2, down- Akt has been observed in PKD [101]. Inhibitors of PI3K,
regulate R1 by facilitating the degradation of protein, and which would be predicted to inactivate Akt and promote
up-regulate R2 expression at the transcriptional level. apoptosis, are currently in a preclinical phase of develop-
One of these analogues (8-Cl-cAMP) has been shown ment [102].
to inhibit growth and induce differentiation in a variety The binding of cytokines to their receptors can also
of human cancer cell lines. Another approach in neoplas- trigger the activation of sphingomyelinases. A marked
tic disease has been to inhibit the synthesis and function reduction in the renal concentration of ceramide and
of PKA1 by the use of R1 mRNA antisense oligonucleo- striking increases in the renal concentrations of glucosyl
tides. The functional cross-talk between EGFR activa- and lactosyl ceramides have been reported in the cpk
tion and PKA1 expression suggests that the combination mice [103]. These may reflect an increase in glucosyl cera-
of EGFR tyrosine kinase inhibitors and PKA1 inhibitors mide synthase activity. The levels of glucosyl and lactosyl
may have synergistic effects. In fact, anti-EGFR antibod- ceramide and the activities of glucosyl ceramide synthase
ies and PKA1 antisense oligonucleotides have a demon- and lactosyl ceramide synthase are markedly increased
strated cooperative inhibitory effect on the growth of in human ADPKD kidneys and in epithelial cell cultures
derived from human ADPKD and cpk kidneys [104].renal cancer xenografts in athymic mice [95].
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Lactosyl ceramide has been found to stimulate the phos- majority of kidneys with noncystic diseases, there is a
phorylation of mitogen-activated protein kinase (MAPK) very low rate of epithelial proliferation, and apoptotic
in proximal tubular epithelial cells from normal human DNA fragmentation is undetectable. On the other hand,
kidney [104]. The effect of drugs capable to inhibit the it is easily detectable in rodent models of PKD and hu-
synthesis of lactosyl ceramide, such as 1-phenyl-2-deca- man ADPKD, involving both cystic and noncystic renal
noylamino-3-morpholino-1-propanol, on the develop- parenchyma [20, 21]. A marked increase in caspase
ment of PKD has not been ascertained [105]. (mainly capase 4)-mediated apoptosis has been described
in kidneys of cpk mice [110]. The exact role of apoptosis
RETINOIDS AND VITAMIN D with respect to cystogenesis is uncertain. A recent study
in the cpk mouse has demonstrated that nuclear expres-The retinoids are a class of biologically active deriva-
sion of Pax 2, which is normally down-regulated in ma-tives of and synthetic compounds structurally related to
ture epithelial cells, is persistent in many epithelial cells.vitamin A, which control normal cell growth, differentia-
tion, and apoptosis during embryonic development and Reducing the Pax 2 gene dose led to an increase in
within epithelial tissues in later life [106]. They exert apoptosis and less severe cystic disease [111]. On the other
their effects by binding to at least six retinoid receptors, hand, the development of renal cysts and renal failure
which are classified into two subfamilies: retinoid acid in knockouts of the antiapoptotic proto-oncogenes Bcl
receptors (RARs) a, b, and g, and retinoid X-receptors 2 and AP2-b suggests that accentuated apoptosis might
(RXRs) a, b, and g (Fig. 3). The diversity of these recep- exert a cystogenic effect. In addition, the high rate of
tors and their binding to DNA as dimers explains the apoptosis in polycystic kidneys may exert a certain de-
complexity of the retinoid signaling mechanisms. The
gree of counterproliferative and counterprotooncogenicbest studied retinoids, 13-cis-retinoid acid, 9-cis-retinoid
effect, which may explain the low incidence of renal cellacid, and all-trans-retinoid acid, occur endogenously at
carcinoma in ADPKD. Although multiple strategies tovery low levels and have been synthesized and adminis-
increase or decrease the rate of apoptosis in tubulartered at pharmacological levels. Retinoids have been used
epithelial cells are possible [112, 113], further studies areas chemopreventive agents in experimental models of
needed to define unambiguously the role of apoptosiscarcinogenesis, as well as in clinical trials, including chemo-
in cystic disease progression and the potential benefitprevention of recurrent bladder carcinoma [107]. The
of treatments acting at various levels of the apoptoticfocus of retinoid drug development is the synthesis of
drugs with selectivity for specific retinoid acid receptors cascade.
and less toxicity. One of these drugs, fenretinide, induces
apoptosis in numerous neoplastic cells, has a favorable
toxicity profile, has been found to be effective in rat and TAXANES
mouse models of bladder carcinogenesis, and is being A role for microtubules in cystogenesis was suggested
tested in large placebo-control studies of chemopreven- by the demonstration that taxol, colchicine, and vinblas-
tion for human bladder cancer. Whether fenretinide or tin reversibly inhibited the formation of cysts by epithe-
other retinoids might be beneficial in the treatment of
lial cells from human and murine polycystic kidneys cul-PKD has not been studied. However, the administration
tured in a collagen matrix. The administration of taxolof N-(4-hydroxyphenyl) retinamide markedly inhibits
to cpk mice markedly inhibited the formation of cysts andcystogenesis in cultures of ADPKD-derived Madin-
prolonged survival. Treatment with other microtubuleDarby canine kidney, and rat epithelial cells in a collagen
active taxanes was also protective to an extent propor-matrix [108].
tional to their ability to bind and promote spontaneousLike the retinoids, biologically active forms of vitamin
assembly of microtubules in vitro, whereas treatment withD inhibit cellular proliferation and induce differentiation
and apoptosis in a variety of cells by binding to a vitamin inhibitors of DNA synthesis was ineffective [114]. The
D receptor. Although the clinical use of vitamin D is mechanism by which stabilization of microtubules was
limited by its calcemic effect, a number of analogues that protective in a rapidly progressive model of PKD is un-
inhibit cell growth without significant calcemic activity certain, but it might have been due to the promotion of
have been synthesized [109]. The effect of these drugs apoptosis [115, 116]. The fact that the administration of
on cystogenesis has not been evaluated. taxol has no protective effect in Han:SPRD rats or pcy/
pcy mice with slowly progressive renal cystic disease sug-
MODULATORS OF PROLIFERATION gests that taxanes are not likely to have a beneficial effect
AND APOPTOSIS in human ADPKD [117]. The administration of taxol also
was not protective in orpk mice, a model of ARPKD lessProliferation and apoptosis are tightly regulated dur-
ing nephrogenesis. In normal mature kidneys and in the rapidly progressive than that in cpk mice [118].
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HORMONAL MODULATORS The administration of a vasopressin V2-receptor (AVP-
V2R) antagonist reduced the severity of the cystic dis-By the time the renal cysts reach a diameter of approxi-
ease and renal insufficiency in cpk/cpk mice, a modelmately 2 mm, they become disconnected from the tubular
characterized by an urinary concentration defect and up-segment from which they derived. Further growth of the
regulation of AVP-V2R and aquaporins 2 and 3 [122].cysts depends on a process of transepithelial fluid secretion.
This observation may be relevant to other experimentalThe driving force is an active transport of chloride from
models of PKD, as well as to human ADPKD andthe basolateral to the apical side. The potential energy
ARPKD, in which there is also a urinary concentrationfor chloride secretion is developed by the sodium pump
defect. Anecdotal observations suggest that the inhibi-(Na1,K1-ATPase) located in the basolateral membranes
tion of secretin release induced by the administration ofof cyst epithelial cells. The chloride entry mechanism
H2 blockers or by octreotide might have a beneficialinto the basolateral membrane is a sodium-potassium-
effect on polycystic kidney and liver disease. Neverthe-chloride, bumetanide-sensitive, cotransporter (NKCC1 or
less, a small prospective study with octreotide failed toBSC2), which utilizes the gradient established by the
demonstrate a benefit [123].sodium pump to bring K and Cl into the cells. Net chlo-
ride transport is accomplished by opening chloride chan-
nels within the apical membrane. Chloride ions flow ANTI-INFLAMMATORY AGENTS
down an electrochemical gradient into the cyst generat- Interstitial inflammation is a consistent finding that
ing increased transepithelial electron activity that in turn develops early and contributes to the progression of the
drives sodium ions through ion selective paracellular renal cystic disease in murine models of PKD and in
pathways. An apical chloride channel that may play a human ADPKD. It is accompanied by local expression
role in cyst fluid accumulation is the cystic fibrosis trans- of chemokines, lymphokines, and other inflammatory
membrane conductance regulator (CFTR). This is sup- mediators [reviewed in 45]. The chemokines are a large
ported by the up-regulation of CFTR in some cysts, by family of secreted, chemotactic, basic proteins of 8 to
whole cell patch clamp studies of ADPKD-derived epi- 10 kD molecular weight selectively targeting different
thelial cells, by the CFTR antisense oligonucleotide- leukocyte subpopulations. They have been divided ac-
induced inhibition of fluid secretion in cyst-derived cell cording to their chemical structure into the C-X-C [for
monolayers, and by the observation of a milder cystic example, interleukin-8 (IL-8)], C-C [monocyte chemo-
phenotype in two patients affected by both ADPKD and tactic protein 1 (MCP-1)] and C (for example, lympho-
cystic fibrosis [119]. On the other hand, attenuation of the toxin) chemokines. Osteopontin is a highly acidic, se-
cystic phenotype was not observed in a third patient with creted glycoprotein that also exhibits chemoattractant
ADPKD and cystic fibrosis (abstract; Persu A, 33rd ASN activity for macrophages. IL-8, MCP-1, and osteopontin
Meeting, 2000) and CFTR does not seem to be important are expressed at low levels in normal renal tubule epithe-
in the autosomal recessive murine orpk model of cystic lial cells. In Han:SPRD rats, MCP-1 and osteopontin are
disease (abstract; Nakanishi T, 33rd ASN Meeting, 2000). expressed at very high levels, primarily over the cystic
The activation of the NKCC1/BSC2 cotransporter and epithelium. Elevated plasma concentrations of IL-6 have
of the chloride channels is regulated by PKA-mediated been reported in patients with ADPKD. High levels of
phosphorylation, which is under hormonal control. The the proinflammatory cytokines tumor necrosis factor-a
secretion of chloride and fluid by cyst-derived epithelial (TNF-a), IL-1, and IL-2 have been found in cyst fluids
cells is stimulated by a number of agonists that stimulate from patients with ADPKD [reviewed in 45]. TNF-a, a
the production of cAMP, such as vasopressin, secretin, major mediator of inflammation and a strong inducer
vasoactive intestinal peptide, prostaglandin E1 and E2, of other cytokines, is produced as a 26 kD membrane-
and cyst activating factor (CAF). Secretin has been shown associated precursor protein that requires proteolytic
to increase the rate of fluid secretion in vivo in renal cleavage to the soluble 17 kD active protein. The TNF-a–
and hepatic cysts of subjects with ADPKD [120]. In converting enzyme (TACE) responsible for this proteo-
addition, testosterone has been found to activate adenyl- lytic cleavage belongs to the family of metalloprotei-
cyclase, increase cellular cAMP, and stimulate the secre- nases. Most metalloproteinase inhibitors have limited
tion of chloride and fluid by monolayers of MDCK cells, potency against TACE, but more selective inhibitors
possibly contributing to the gender dimorphism ob- currently under development and other strategies for
served in human ADPKD and rat models of PKD [121]. inhibiting TNF-a may be of interest in the treatment of
The molecular mechanisms by which fluid is secreted ADPKD (discussed later in this article) [124, 125]. The
by cyst-derived epithelial cells can potentially be tar- importance of inflammation in the pathogenesis of
geted for treatment. Whether the inhibition of the baso- ADPKD is highlighted by studies in which methylpred-
lateral NKCC1/BSC2 cotransporter by loop diuretics nisolone, a steroidal anti-inflammatory that inhibits
phospholipase A2 and cyclooxygenase-2 (COX-2), atten-might be of therapeutic value has not been ascertained.
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uated renal enlargement and renal dysfunction in two and the degree to which they may contribute, not only to
the development of hypertension and vascular lesions, butrodent models of renal cystic disease [126]. Whether
other anti-inflammatory drugs, such as COX-2 inhibitors also to the proliferation of the cystic epithelium and
interstitial inflammation and fibrosis, have been reviewedor lipooxygenase inhibitors, might have protective ef-
fects on the development of PKD that outweigh their elsewhere [45] and are only briefly summarized here.
There is convincing evidence that the intrarenal renin-potential toxicity has not been ascertained.
angiotensin system is activated in human ADPKD, as
well as in experimental models of PKD, as least in the
INHIBITORS OF MATRIX early stages. The administration of a converting enzyme
METALLOPROTEINASES inhibitor or an angiotensin II type 1 (AT-1) receptor an-
Matrix metalloproteinases are a group of zinc depen- tagonist to Han:SPRD cy/1 rats between 3 to 4 weeks and
dent enzymes that include the interstitial collagenases 10 to 20 weeks of age has had a protective effect on the
(MMP-1, MMP-8, and MMP-13), stromelysins (MMP-3 severity of the renal cystic disease and renal function as
and MMP-10), gelatinases (MMP-2 and MMP-9), and compared with other antihypertensive regiments [129–131].
membrane-type metalloproteinases [127]. They are in- On the other hand, enalaprilat and hydralazine adminis-
volved in the remodeling and turnover of the extracellu- tered to Han:SPRD rats between 3 and 40 weeks of age
lar matrix and have been implicated in the pathogenesis were equally protective on the renal function as reflected
of PKD by controlling matrix degradation and growth by the level of serum creatinine, although only enalapri-
factor activation. While the levels of tissue inhibitors lat reduced proteinuria and kidney size [131].
of MMPs (TIMPS) have been found to be uniformly Elevated plasma levels and the presence of endothelin
elevated in tissues or cultured cells from human polycys- in cyst fluid have been demonstrated in human ADPKD
tic kidneys or livers and in renal tissues from Han:SPRD [132, 133] and cpk/cpk mice [134]. Elevated renal tissue
rats or cpk mice, the observations on MMPs have been levels of endothelin 1 have been found in Han:SPRD
less consistent [reviewed in 123]. A recent study has shown rats. On the other hand, the expression of endothelin
elevated serum or plasma levels of MMP-1, MMP-9, and type A and type B receptors has been found to be in-
TIMP-1 in patients with ADPKD [128]. MMPs are also creased in the cpk/cpk mouse, but reduced in the Han:
thought to play an important role in tumor invasion, SPRD rat. Endothelin-1 (ET-1) transgenic mice have
metastases, and angiogenesis. A number of selective in- a cystic phenotype [135]. The acute administration of
hibitors of specific MMPs are currently in phase 1, 2, or bosentan, a mixed endothelin receptor antagonist, sig-
3 clinical trials for a variety of neoplastic diseases [127]. nificantly decreased the mean arterial blood pressure
Treatment of Han:SPRD rats with batimastat, a broad and glomerular filtration rate and increased the renal
blood flow in Han:SPRD rats, but had no significantspectrum MMP inhibitor, has had a beneficial effect on
effect in the control rats [136]. Whether the chronic ad-cyst number and kidney weight (abstract; Obermuller
ministration of endothelin antagonists might have a pro-N, Netherlands PKD Workshop, 2000). Recently, specific
tective effect on the development of PKD has not beenTACE inhibitors have been reported to inhibit TGF-a
ascertained.secretion from immortalized cystic collecting tubule cells
Little is known on the role of nitric oxide (NO) in thein vitro and cystogenesis in bpk mice in vivo (abstract;
pathogenesis of ADPKD. Nitric oxide has potentiallyDell K, 33rd ASN Meeting, 2000). Therefore, the role of
beneficial (preservation of renal blood flow and glomeru-MMPs in the pathogenesis of ADPKD and their poten-
lar filtration, inhibition of platelet adherence to endothe-tial as a target for intervention deserve further study.
lial surfaces) and detrimental (cytotoxicity from oxidative
damage) effects. Both beneficial and detrimental effects
TREATMENT OF HYPERTENSION AND from NO inhibition have been described in a variety of
NEPHROANGIOSCLEROSIS experimental models of glomerular disease and acute renal
Hypertension often develops early in the course of failure [reviewed in 59]. The administration of l-arginine
ADPKD and is a predictor of renal functional decline. in the rat remnant kidney model, which is characterized
It is accompanied by an increase in renal vascular resis- by a reduced renal generation of NO, has produced vari-
tance and filtration fraction, resetting of the pressure- able results: protective at a low and detrimental at a high
natriuresis relationship, salt sensitivity, and normal or dose. The renal production of NO has been found to be
increased extracellular fluid volume, plasma volume, and reduced in Han:SPRD rats (abstract; Wang D, 33rd ASN
cardiac output. It is accompanied by severe sclerosis of Meeting, 2000) [58]. The administration of the NO synthase
the preglomerular vessels, even early in the course of the inhibitor NG-nitro-l-arginine methyl ester (L-NAME) and
disease. Therefore, early detection and treatment of hy- l-arginine had only a modest, gender-dependent (ob-
pertension are of the upmost importance in management served only in the male animals) overall effect on the
severity of the cystic disease [59]. On the other hand,of these patients. The role of the different vasoactive factors
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